Edgewise doses first patient in heart failure trial

Edgewise Therapeutics (EWTX) dosed the first patient in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a treatment for heart failure with preserved ejection fraction (HFpEF). The trial will enroll 90 adults and evaluate safety, tolerability, and efficacy of EDG-15400. Data will be presented at HFSA 2026. HFpEF affects cardiac relaxation, and EDG-15400 aims to address this.

Edgewise Therapeutics (EWTX) announced preclinical data showing its cardiac sarcomere modulator EDG-7500 improves cardiac relaxation while preserving systolic function. The company will host a webcast to discuss these findings. EDG-7500 is being evaluated for hypertrophic cardiomyopathy (HCM) and a Phase 3 trial is expected to begin in Q4 2026. Early clinical observations align with preclinical data, and a peer-reviewed publication is set to release.

Edgewise Therapeutics (EWTX) saw significant options activity, with a 6,000-contract diagonal spread indicating a bullish stance. Traders rolled ITM Sep $45 calls to OTM Oct $50 calls, targeting an 8.4% rally. EWTX stock is up 197% over the past year, driven by a $2.65B business sale. Analysts have mixed views on its valuation and profitability.

Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2026 results and said its EDG-7500 12-week Phase 2 CIRRUS-HCM trial showed positive top-line data in obstructive and nonobstructive HCM, with Phase 3 planned for Q4 2026. In July 2026, it completed selling sevasemten and its muscular dystrophy business to Servier for $1.55B upfront plus up to $1.1B milestones. Q2 cash was about $460.7M; net loss was $57.3M.

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemte

Servier completed its acquisition of Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones, after regulatory clearance. The deal adds sevasemten, in a pivotal Becker muscular dystrophy cohort and Phase 2 Duchenne study. (EWTX)